| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | EB-05, NI-0101 |
| Cas No. | |
| Clonality | |
| Expression System | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Research Grade Paridiprubart (HT205016) is a monoclonal antibody.Specifications
| Host Species | Humanized |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Target | Toll-like receptor 4, TLR4, CD284, hToll |
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | O00206 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
Toll-like receptor 4 is a ~95 kDa protein. Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways. At the plasma membrane, cooperates with LY96 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+). Mechanistically, acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Alternatively, CD14-mediated TLR4 internalization via endocytosis is associated with the initiation of a MYD88-independent signaling via the TICAM1-TBK1-IRF3 axis leading to type I interferon production.
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Arbour, NC. et al. (2000) Nature genetics 25, 187-91. PMID: 10835634
2. Bulut, Y. et al. (2005) The Journal of biological chemistry 280, 20961-7. PMID: 15809303
3. Jung, SB. et al. (2006) Infection and immunity 74, 2686-96. PMID: 16622205
4. Georgel, P. et al. (2007) Virology 362, 304-13. PMID: 17292937
5. Kim, F. et al. (2007) Circulation research 100, 1589-96. PMID: 17478729
6. Stewart, CR. et al. (2010) Nature immunology 11, 155-61. PMID: 20037584
7. Schmidt, M. et al. (2010) Nature immunology 11, 814-9. PMID: 20711192
8. Estruch, M. et al. (2013) Atherosclerosis 229, 356-62. PMID: 23880187
9. Tatematsu, M. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 196, 3865-76. PMID: 27022195
10. Xiahou, Z. et al. (2017) Nature communications 8, 950. PMID: 29038465
